Valuation : Harrow, Inc.

Market Cap 1.37B 1.18B 1.11B 1.01B 1.89B 131B 1.91B 13.25B 5.1B 66.5B 5.15B 5.04B 211B P/E 2026 *
-450x
P/E 2027 * 16.5x
Enterprise Value 1.37B 1.18B 1.11B 1.01B 1.89B 131B 1.91B 13.25B 5.1B 66.5B 5.15B 5.04B 211B EV / Sales 2026 *
3.91x
EV / Sales 2027 * 2.54x
Free-Float
84.62%
Yield 2026 *
-
Yield 2027 * -
1 day-2.58%
1 week-4.39%
Current month-0.89%
1 month-10.12%
3 months+1.89%
6 months+1.39%
Current year-25.35%
1 week 36.37
Extreme 36.37
38.53
1 month 36.25
Extreme 36.25
42.71
Current year 28.54
Extreme 28.5401
54.85
1 year 28.54
Extreme 28.5401
54.85
3 years 7.6
Extreme 7.6
59.23
5 years 5.4
Extreme 5.4
59.23
10 years 1.35
Extreme 1.35
59.23
Manager TitleAgeSince
Chief Executive Officer 53 17/12/2011
President 43 21/08/2025
Compliance Officer - 01/10/2023
Director TitleAgeSince
Chairman 53 19/08/2021
Director/Board Member 57 31/03/2022
Director/Board Member 71 26/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 A Exercice

Chief Technology Officer

33,750 0.0905%
5/18/26 A Buy

Director

1,000 0.0027%
5/18/26 A Buy

Director

1,000 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-2.58%-4.39%-5.89%+146.50% 1.37B
-0.11%-3.16%+48.82%+91.49% 1,001B
-0.27%-4.34%+51.52%+65.89% 642B
+1.63%-2.00%+20.49%+71.12% 451B
-0.63%-3.09%+29.84%+34.59% 340B
+0.43%-14.61%+11.32%+27.26% 263B
+0.93%-3.19%-1.31%+8.41% 247B
-2.25%-13.88%+37.33%+47.43% 207B
-0.90%-5.06%-18.47%-57.75% 197B
-0.58%-4.24%+25.65%+90.54% 180B
Average -0.36%-5.41%+19.93%+52.55% 352.77B
Weighted average by Cap. +0.08%-4.65%+31.93%+57.21%

Financials

2026 *2027 *
Net sales 351M 302M 285M 259M 485M 33.53B 489M 3.39B 1.3B 17.01B 1.32B 1.29B 54.02B 540M 464M 438M 399M 746M 51.63B 753M 5.22B 2.01B 26.19B 2.03B 1.98B 83.18B
Net income -2.98M -2.56M -2.42M -2.2M -4.12M -285M -4.15M -28.79M -11.08M -144M -11.19M -10.94M -459M 87.64M 75.37M 71.11M 64.78M 121M 8.38B 122M 847M 326M 4.25B 329M 322M 13.5B
Net Debt - -
Logo Harrow, Inc.
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Employees
373
Date Price Change Volume
10/09/26 $36.58 -2.58% 371,169
09/09/26 $37.55 -0.79% 354,693
08/09/26 $37.85 -1.79% 532,035
04/09/26 $38.54 +0.73% 229,022
03/09/26 $38.26 -2.02% 449,776
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
36.58USD
Average target price
65.00USD
Spread / Average Target
+77.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HROW Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!